… patients who contracted COVID-19 and received Paxlovid or Molnupiravir treatment within
5 days of COVID-19 diagnosis, we examined the rates of COVID-19 rebound in patients who …

… The patient-compliant oral dosage form of molnupiravir may hit the market in the first or …
of COVID-19, the molnupiravir development program moved to the treatment of COVID-19 […

… trial against COVID-19 15, 16 and there are some concerns about molnupiravir's potential
… , 17 this study aimed to evaluate molnupiravir-related adverse events in COVID-19 patients. …

… coronavirus 2 (SARS-CoV-2) and prevent progression to severe coronavirus disease 2019
(COVID-19). … efficacy of the nucleoside analog molnupiravir in 202 unvaccinated participants …

… or death in patients with mild or moderate COVID-19, which has … ) of the patients in the
molnupiravir group were hospitalized or … group, implying that molnupiravir reduced the mortality or …

… patients with mild-to-moderate COVID-19. In this study, we evaluate the efficacy and safety
of molnupiravir in Indian patients … The results of the phase 3 study in mild COVID-19 patients …

… molnupiravir in the enrolled patients was generally acceptable, with only 11.88% of
molnupiravir … Moreover, rapid initiation of molnupiravir within 1 day of COVID-19 onset was an …

… Various pharmaceutical companies in India have recently reported limited findings from the
interim analysis of phase III trials of molnupiravir among Indian COVID-19 patients aged 18–…

… in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor …
patients (28 of 385) who received molnupiravir as part of the phase III trial and 14.1% of patients …

… The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines of …